In part 2 of their Guest Commentary series, Precision’s Todd Edgar, Alex Grosvenor, and Kellie Rademacher highlight the takeaways of the NOR-SWITCH trial and how the EU’s view of biosimilars as therapeutic alternatives is influencing US policy.
To read the full article, please click here.